Information Provided By: 
Fly News Breaks for November 7, 2016
UTHR, STDY
Nov 7, 2016 | 07:29 EDT
H.C. Wainwright analyst Andrew Fein started SteadyMed (STDY) with a Buy rating and $10 price target. The company's disposable treprostinil pump offers an "atypical biotech investment opportunity," Fein tells investors in a research note. He sees a "high likelihood" for a ruling in favor of SteadyMed by next spring in the company's legal challenge of a United Therapeutics' (UTHR) key treprostinil patent.
News For STDY;UTHR From the Last 2 Days
There are no results for your query STDY;UTHR
